A registry study of elranatamab for relapsed multiple myeloma in China
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study collects information from patients with relapsed or refractory multiple myeloma who are taking the drug elranatamab as part of their normal care. It aims to learn more about how this treatment works in real-world Chinese patients, which may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have relapsed or refractory multiple myeloma, meaning the disease has returned or stopped responding to treatment.
- You have already been treated with at least one of each of these three drug types: a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody, in any order.
- You are already taking elranatamab or plan to start it as part of your regular care, not in a research trial.
- You have not had any other cancer before your multiple myeloma diagnosis.
- You are not participating in any other interventional (treatment) clinical trials for multiple myeloma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
This trial tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to treatment, specifically after they have received a therapy named idecabtagene vicleucel (Abecma). It aims to see if elranatamab can help control the disease.
This trial tests a new drug, elranatamab, for people with multiple myeloma who recently received a CAR-T cell therapy (cilta-cel) but still have high-risk features. The goal is to see if elranatamab can help keep the cancer from coming back.
Hear when a new TCE-RRMM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.